Ovarian Cancer
Conditions
Keywords
Relapsed, Refractory, anti-PD-1 antibody, Manganese, Chemotherapy
Brief summary
Epithelial ovarian cancer is the most lethal gynecologic malignancy, and most patients eventually relapse and develop resistance to available therapies. Immune checkpoint inhibitors have shown limited overall efficacy in recurrent ovarian cancer, partly because of its immunosuppressive tumor microenvironment. Manganese (Mn2+) can activate the cGAS-STING pathway and may enhance antitumor immunity and the therapeutic effects of PD-1 blockade combined with chemotherapy. Following encouraging findings from an early-phase study, a randomized, single-blind, placebo-controlled phase II trial showed that the addition of manganese chloride to anti-PD-1 antibody, nab-paclitaxel, and cisplatin improved clinical outcomes compared with placebo, with an overall manageable safety profile. Based on these findings, this phase III trial is designed to confirm the efficacy and further evaluate the safety of Mn2+-primed immunochemotherapy in patients with advanced ovarian cancer.
Interventions
Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
DRUGNab-paclitaxel
Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/ mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
DRUGPlacebo
Administered by inhalation twice per week in the first 3-week cycle, and then inhaled twice in the first week of each 3-week cycle thereafter
Sponsors
Chinese PLA General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically or cytologically confirmed epithelial ovarian cancer, primary fallopian tube cancer, or peritoneal cancer. 2. Patients who have received at least two prior lines of systemic therapy, including at least one platinum-based regimen. 3. Patients who experienced disease progression during or within 6 months after completion of the most recent line of systemic therapy. Note: This most recent therapy is not required to be platinum-based and may be any systemic treatment (chemotherapy, targeted therapy, or other anticancer therapy). 4. Patients with at least one measurable lesion. 5. Patients who have received immunotherapy (anti-PD-1 antibodies, anti-PD-L1 antibodies), or bevacizumab, are not restricted from enrollment. 6. Expected survival of more than 6 months. 7. Age over 18 years. 8. Patient weight \> 40 kg. 9. ECOG performance status ≤ 2. 10. Peripheral blood white blood cell count \> 3.5×10 /L. 11. Bone marrow reserve and liver and kidney function (the following laboratory tests should be performed before initial treatment to prove): * Absolute neutrophil count (ANC) ≥ 1,000/mm ; * Hemoglobin \> 80 g/dL; * Platelet count \> 80,000/mm ; * ALT/AST \< 3×ULN; * Serum creatinine \< 3×ULN; * Total bilirubin level \< 3×ULN. 12. No significant hereditary diseases. 13. Normal liver and kidney biochemical indicators. 14. Completed the last systemic anticancer therapy at least 4 weeks prior to enrollment, with resolution of all treatment-related adverse events to grade ≤1 according to NCI-CTCAE v5.0, with the exception of alopecia and other clinically insignificant toxicities deemed acceptable by the investigator. 15. No treatment with paclitaxel (albumin-bound) plus platinum in the past 3 months. 16. Voluntary participation and signing of informed consent, compliance with the trial treatment plan and visit schedule, and cooperation in observing adverse events and efficacy.
Exclusion criteria
1. Absolute neutrophil count (ANC) \< 1×10 /L or platelets \< 80×10 /L or hemoglobin \< 80 g/dL (according to the normal values of the clinical trial center）. 2. Serum total bilirubin levels higher than 3 times the upper limit of the reference range. 3. ALT, AST, or ALP levels higher than 3 times the upper limit of the reference range when there are no liver metastases; ALT, AST, or ALP levels higher than 5 times the upper limit of the reference range when there are liver metastases. 4. Patients receiving known strong inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin or St. John's Wort) of CYP3A4, or strong inhibitors (e.g., gemfibrozil) or inducers of CYP2C8; patients receiving treatment with potent P-gp inhibitors or inducers, or patients who cannot stop treatment with these agents for 2 weeks before the start of the study. 5. Subjects' bowel obstruction or requirement for bowel obstruction-related interventions within 3 weeks prior to first study drug administration; subjects with incomplete bowel obstruction who have returned to normal within 1 month before the first dose of the experimental drug can be included in the study after discussion by the researchers. 6. Patients with severe or uncontrolled ascites, defined as either of the following: a) symptomatic ascites corresponding to CTCAE ≥ Grade 2; b) history of therapeutic paracentesis for ascites within 3 weeks prior to enrollment. 7. Organ failure: * Heart: Grade III or IV. * Liver: Grade C according to Child-Pugh B liver function classification. * Kidney: Renal failure and uremia. * Lung: Severe respiratory failure symptoms. * Brain: Consciousness disorders. 8. T-cell tumors such as T-cell lymphoma or T-cell leukemia. 9. Major surgery within 4 weeks before enrollment, or planned major surgery during the study (excluding diagnostic surgery). 10. HIV antibody positive, or other acquired, congenital immunodeficiency diseases, or patients with a history of organ transplantation. 11. History of Parkinson's disease or epilepsy, or occurrence of diseases that can induce seizures within 12 months before the study (including a history of transient ischemic attack, stroke, traumatic brain injury with consciousness disorders). 12. CTCAE grade 2 infections that do not respond to treatment or active clinically serious infections with CTCAE \> Grade 2. 13. Patients with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment. 14. Patients with a history of allergic reactions to study drug components or suspected allergies. 15. Chronic diseases requiring immunotherapy or hormone therapy. 16. Patients who have received any investigational drug treatment within 30 days before the first dose of the trial drug. 17. Subjects with symptoms of brain or leptomeningeal metastasis. 18. Subjects with a history of malignant tumors (non-study tumor) within 3 years before the first dose of the trial drug. 19. History of the following diseases: interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases including diabetes, hypertension, pulmonary fibrosis, acute lung disease, abdominal infection, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 12 months | PFS time was measured from study entry to the first documentation of disease progression or death. Disease progression was determined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 24 months | OS time was measured from the study entry to the date of death. |
| Object response rate (ORR) | 24 months | ORR is defined as the proportion of subjects who achieved a partial response (PR) or complete response (CR) according to the RECIST V1.1. |
| Number of Subjects with treatment-related adverse events (AEs) | 12 months | Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit. |
Countries
China
Contacts
CONTACTWeidong Han
Outcome results
None listed